{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:53:16Z","timestamp":1790182396637,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background and rationale<\/jats:title>\n            <jats:p>Progressive familial intrahepatic cholestasis (PFIC) associated with myosin 5B deficiency is a rare liver disease characterised by elevated serum bile acids (sBAs) and severe pruritus. The objective of this study was to evaluate treatment with the ileal bile acid transporter inhibitor odevixibat in affected children.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This was a retrospective analysis of five children with a diagnosis of PFIC associated with myosin 5B deficiency and pruritus refractory to treatment with rifampicin and ursodeoxycholic acid, starting odevixibat treatment (37.2\u2013120\u00a0\u00b5g\/kg.day) between 15 months and 10 years of age. Clinical and laboratory data were collected regularly, including liver biochemistry and treatment history. Pruritus and sleep disorders were rated on a four-point Likert scale (absent, mild, moderate or severe).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In the year before starting odevixibat, all patients presented with moderate to severe refractory pruritus. Four patients had sleep disturbances. One patient had a history of microvillus inclusion disease and was parenterally fed during his first year of life. In the year prior to initiating odevixibat, sBA levels were &gt;\u2009150 \u00b5mol\/L and total bilirubin levels were &gt;\u200925 \u00b5mol\/L in all patients. Within six months after starting odevixibat, sBA levels normalised to &lt;\u200910 \u00b5mol\/L and total bilirubin fell to &lt;\u200915 \u00b5mol\/L. Bilirubin and sBA levels remained mostly normal throughout the treatment period (from 22 to 39 months) in four patients. Pruritus and sleep disturbances improved in the first three months and disappeared completely on treatment in four patients. In two patients, compliance and access to treatment were limited, which may explain the fluctuations in treatment response. In one patient, odevixibat treatment was discontinued following an episode of infectious gastroenteritis leading to a rise in sBA and symptom recurrence which did not respond to treatment reinitiation. Digestive tolerability of odevixibat was good; no new or worsening gastrointestinal symptoms were observed in any child.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This case series indicates that treatment with odevixibat is effective in children with myosin 5B-related PFIC and encourages further research into the utility of this medication in rare forms of PFIC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03728-x","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T12:43:55Z","timestamp":1747053835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Odevixibat therapy in progressive familial intrahepatic cholestasis with MYO5B variants: a retrospective case series"],"prefix":"10.1186","volume":"20","author":[{"given":"Bertrand","family":"Roquelaure","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sciveres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tassos","family":"Grammatikopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Lurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folke","family":"Freudenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalila","family":"Habes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Thevathasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatine","family":"Elaraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1546-3193","authenticated-orcid":false,"given":"Emmanuel","family":"Gonzales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"issue":"4","key":"3728_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cld.2018.06.003","volume":"22","author":"LN Bull","year":"2018","unstructured":"Bull LN, Thompson RJ. Progressive Familial intrahepatic cholestasis. Clin Liver Dis. 2018;22(4):657\u201369.","journal-title":"Clin Liver Dis"},{"key":"3728_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-4-1","volume":"4","author":"A Davit-Spraul","year":"2009","unstructured":"Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive Familial intrahepatic cholestasis. Orphanet J Rare Dis. 2009;4:1.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"3728_CR3","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.4254\/wjh.v13.i12.2024","volume":"13","author":"V Vinayagamoorthy","year":"2021","unstructured":"Vinayagamoorthy V, Srivastava A, Sarma MS. Newer variants of progressive Familial intrahepatic cholestasis. World J Hepatol. 2021;13(12):2024\u201338.","journal-title":"World J Hepatol"},{"issue":"1","key":"3728_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/hep.28779","volume":"65","author":"E Gonzales","year":"2017","unstructured":"Gonzales E, Taylor SA, Davit-Spraul A, Th\u00e9baut A, Thomassin N, Guettier C, et al. MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease. Hepatology. 2017;65(1):164\u201373.","journal-title":"Hepatology"},{"issue":"5","key":"3728_CR5","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1002\/hep.29020","volume":"65","author":"YL Qiu","year":"2017","unstructured":"Qiu YL, Gong JY, Feng JY, Wang RX, Han J, Liu T, et al. Defects in myosin VB are associated with a spectrum of previously undiagnosed low \u03b3-glutamyltransferase cholestasis. Hepatology. 2017;65(5):1655\u201369.","journal-title":"Hepatology"},{"issue":"4","key":"3728_CR6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/MPG.0b013e3181fb4559","volume":"52","author":"U Halac","year":"2011","unstructured":"Halac U, Lacaille F, Joly F, Hugot JP, Talbotec C, Colomb V, et al. Microvillous inclusion disease: how to improve the prognosis of a severe congenital enterocyte disorder. J Pediatr Gastroenterol Nutr. 2011;52(4):460\u20135.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"3728_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/hep.26974","volume":"60","author":"M Girard","year":"2014","unstructured":"Girard M, Lacaille F, Verkarre V, Mategot R, Feldmann G, Grodet A, et al. MYO5B and bile salt export pump contribute to cholestatic liver disorder in microvillous inclusion disease. Hepatology. 2014;60(1):301\u201310.","journal-title":"Hepatology"},{"issue":"6","key":"3728_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1097\/MPG.0000000000000526","volume":"59","author":"A Perry","year":"2014","unstructured":"Perry A, Bensallah H, Martinez-Vinson C, Berrebi D, Arbeille B, Salomon J, et al. Microvillous atrophy: atypical presentations. J Pediatr Gastroenterol Nutr. 2014;59(6):779\u201385.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"3728_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/hep.31002","volume":"72","author":"AW Overeem","year":"2020","unstructured":"Overeem AW, Li Q, Qiu YL, Cart\u00f3n-Garc\u00eda F, Leng C, Klappe K, et al. A molecular mechanism underlying Genotype-Specific intrahepatic cholestasis resulting from MYO5B mutations. Hepatology. 2020;72(1):213\u201329.","journal-title":"Hepatology"},{"key":"3728_CR10","doi-asserted-by":"crossref","unstructured":"Hess MW, Krainer IM, Filipek PA, Witting B, Gutleben K, Vietor I et al. Advanced microscopy for liver and gut ultrastructural pathology in patients with MVID and PFIC caused by MYO5B mutations. J Clin Med. 2021;10(9).","DOI":"10.3390\/jcm10091901"},{"issue":"2","key":"3728_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/MPG.0000000000002740","volume":"71","author":"I Cockar","year":"2020","unstructured":"Cockar I, Foskett P, Strautnieks S, Clinch Y, Fustok J, Rahman O, et al. Mutations in myosin 5B in children with Early-onset cholestasis. J Pediatr Gastroenterol Nutr. 2020;71(2):184\u20138.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"3728_CR12","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1097\/MPG.0000000000003399","volume":"74","author":"L Matarazzo","year":"2022","unstructured":"Matarazzo L, Bianco AM, Athanasakis E, Serveres M, Francalanci P, Cenacchi G, et al. MYO5B gene mutations: A not negligible cause of intrahepatic cholestasis of infancy with normal Gamma-Glutamyl transferase phenotype. J Pediatr Gastroenterol Nutr. 2022;74(5):e115\u201321.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"3728_CR13","doi-asserted-by":"crossref","unstructured":"Aldrian D, Vogel GF, Frey TK, Ayy\u0131ld\u0131z Civan H, Aksu A, Avitzur Y et al. Congenital diarrhea and cholestatic liver disease: phenotypic spectrum associated with MYO5B mutations. J Clin Med. 2021;10(3).","DOI":"10.3390\/jcm10030481"},{"issue":"4","key":"3728_CR14","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/hep.31430","volume":"72","author":"SCD van IJzendoorn","year":"2020","unstructured":"van IJzendoorn SCD, Li Q, Qiu YL, Wang JS, Overeem AW. Unequal effects of myosin 5B mutations in liver and intestine determine the clinical presentation of Low-Gamma-Glutamyltransferase cholestasis. Hepatology. 2020;72(4):1461\u20138.","journal-title":"Hepatology"},{"key":"3728_CR15","unstructured":"Online Mendelian Inheritance in Man [Internet]. 2022 [cited February 2023]. Available from: https:\/\/www.omim.org\/entry\/619868"},{"issue":"10","key":"3728_CR16","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s12098-021-03848-9","volume":"88","author":"BB Lal","year":"2021","unstructured":"Lal BB, Sood V, Khanna R, Alam S. Novel variations in MYO5B presenting as isolated intrahepatic cholestasis: Long-Term outcome after partial internal biliary diversion. Indian J Pediatr. 2021;88(10):1052.","journal-title":"Indian J Pediatr"},{"issue":"15","key":"3728_CR17","first-page":"1781","volume":"81","author":"ED Deeks","year":"2021","unstructured":"Deeks ED, Odevixibat. First Approval Drugs. 2021;81(15):1781\u20136.","journal-title":"First Approval Drugs"},{"issue":"5","key":"3728_CR18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s12072-020-10070-w","volume":"14","author":"SJ Karpen","year":"2020","unstructured":"Karpen SJ, Kelly D, Mack C, Stein P. Ileal bile acid transporter Inhibition as an anticholestatic therapeutic target in biliary Atresia and other cholestatic disorders. Hepatol Int. 2020;14(5):677\u201389.","journal-title":"Hepatol Int"},{"issue":"16","key":"3728_CR19","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1080\/14656566.2022.2140040","volume":"23","author":"SM Bedoyan","year":"2022","unstructured":"Bedoyan SM, Lovell OT, Horslen SP, Squires JE. Odevixibat: a promising new treatment for progressive Familial intrahepatic cholestasis. Expert Opin Pharmacother. 2022;23(16):1771\u20139.","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"3728_CR20","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","volume":"7","author":"RJ Thompson","year":"2022","unstructured":"Thompson RJ, Arnell H, Artan R, Baumann U, Calvo PL, Czubkowski P, et al. Odevixibat treatment in progressive Familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2022;7(9):830\u201342.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"3728_CR21","doi-asserted-by":"publisher","first-page":"100782","DOI":"10.1016\/j.jhepr.2023.100782","volume":"5","author":"RJ Thompson","year":"2023","unstructured":"Thompson RJ, Artan R, Baumann U, Calvo PL, Czubkowski P, Dalgic B, et al. Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive Familial intrahepatic cholestasis. JHEP Rep. 2023;5(8):100782.","journal-title":"JHEP Rep"},{"issue":"6","key":"3728_CR22","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1097\/j.pain.0000000000002820","volume":"164","author":"JS Blythe","year":"2023","unstructured":"Blythe JS, Thomaidou MA, Peerdeman KJ, van Laarhoven AIM, van Schothorst MME, Veldhuijzen DS, et al. Placebo effects on cutaneous pain and itch: a systematic review and meta-analysis of experimental results and methodology. Pain. 2023;164(6):1181\u201399.","journal-title":"Pain"},{"issue":"7","key":"3728_CR23","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S2468-1253(24)00080-3","volume":"9","author":"AG Miethke","year":"2024","unstructured":"Miethke AG, Moukarzel A, Porta G, Covarrubias Esquer J, Czubkowski P, Ordonez F, et al. Maralixibat in progressive Familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024;9(7):620\u201331.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"3728_CR24","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/hep.23539","volume":"51","author":"A Davit-Spraul","year":"2010","unstructured":"Davit-Spraul A, Fabre M, Branchereau S, Baussan C, Gonzales E, Stieger B, et al. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive Familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology. 2010;51(5):1645\u201355.","journal-title":"Hepatology"},{"issue":"7","key":"3728_CR25","doi-asserted-by":"publisher","first-page":"104245","DOI":"10.1016\/j.ejmg.2021.104245","volume":"64","author":"DBE van Wessel","year":"2021","unstructured":"van Wessel DBE, Gonzales E, Hansen BE, Verkade HJ. Defining the natural history of rare genetic liver diseases: lessons learned from the NAPPED initiative. Eur J Med Genet. 2021;64(7):104245.","journal-title":"Eur J Med Genet"},{"issue":"2","key":"3728_CR26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/liv.15104","volume":"42","author":"L Wang","year":"2022","unstructured":"Wang L, Qiu YL, Xu HM, Zhu J, Li SJ, OuYang WX, et al. MYO5B-associated diseases: novel liver-related variants and genotype-phenotype correlation. Liver Int. 2022;42(2):402\u201311.","journal-title":"Liver Int"},{"issue":"2","key":"3728_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/apt.13457","volume":"43","author":"H Graffner","year":"2016","unstructured":"Graffner H, Gillberg PG, Rikner L, Marschall HU. The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation. Aliment Pharmacol Ther. 2016;43(2):303\u201310.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03728-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03728-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03728-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T12:43:58Z","timestamp":1747053838000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03728-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3728"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03728-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written consent to participate in the clinical trial or the compassionate use programme was obtained from the parents of all participating children before administration of odevixibat. The protocols of both the clinical trial and the compassionate use programme were submitted to and approved by the relevant institutional review boards or ethics committees in each country.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EG is a consultant at Albireo\/Ipsen, Theravia, Mirum, and Vivet; and advisory board member at Ipsen and Mirum. TG has received consultancy fees from Albireo\/Ipsen. MS declares consultancy fees from Albireo\/Ipsen and Mirum. At the time of this study, LT and FE were employees of Albireo Pharma Inc, who developed odevixibat, and FE is a current employee of Ipsen, the current marketing authorisation holder. BR, EL, FF, DH declare no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"227"}}